Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 4/20 | 0.53 |
| ▸ | TUBB | P07437 | 4/20 | 0.53 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 0.53 |
| ▸ | TUBA1B | P68363 | 4/20 | 0.53 |
| ▸ | TUBA4A | P68366 | 4/20 | 0.53 |
| ▸ | TUBB4B | P68371 | 4/20 | 0.53 |
| ▸ | TUBB3 | Q13509 | 4/20 | 0.53 |
| ▸ | TUBB2A | Q13885 | 4/20 | 0.53 |
| ▸ | TUBB8 | Q3ZCM7 | 4/20 | 0.53 |
| ▸ | TUBA3E | Q6PEY2 | 4/20 | 0.53 |
| ▸ | TUBA1A | Q71U36 | 4/20 | 0.53 |
| ▸ | TUBA1C | Q9BQE3 | 4/20 | 0.53 |
| ▸ | TUBB6 | Q9BUF5 | 4/20 | 0.53 |
| ▸ | TUBB2B | Q9BVA1 | 4/20 | 0.53 |
| ▸ | TUBB1 | Q9H4B7 | 4/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | FYN | P06241 | 1/20 | 0.43 |
| ▸ | TNFRSF1A | P19438 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6962651 | 0.86 | LMNA (0.47) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL6962330 | 0.81 | TUBB4A (0.44) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL6967733 | 0.80 | GAA (0.57) | TSHRSMN1; SMN2 | |
| SCHEMBL7816206 | 0.78 | AOC3 (0.43) | TSHRSMN1; SMN2 | |
| SCHEMBL477483 | 0.77 | HPGD (0.49) | — | |
| SCHEMBL2963101 | 0.77 | ALOX5 (0.50) | — | |
| SCHEMBL6001763 | 0.76 | HTT (0.45) | TSHRSMN1; SMN2 | |
| SCHEMBL6001757 | 0.76 | HTT (0.45) | TSHRSMN1; SMN2 | |
| SCHEMBL6001753 | 0.76 | HTT (0.45) | TSHRSMN1; SMN2 | |
| SCHEMBL1539305 | 0.75 | TUBB4A (0.39) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6613804-B2 | Treatment of hypertension, cardiovascular disease, pulmonary hypertension, erythropoietin-mediated vasoconstriction, endotoxin shock, pulmonary hypertension, anaphylactic shock and hemorrhagic shock | ENCYSIVE PHARMACEUTICALS, INC. | 2003-09-02 | — | — | US | disclosed |
| EP-0819125-B1 | THIENYL-, FURYL-, PYRROLYL- AND BIPHENYLSULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | TEXAS BIOTECHNOLOGY CORP (US) | 2003-06-18 | — | — | EP | disclosed |
| US-20020095041-A1 | Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin | ENCYSIVE PHARMACEUTICALS INC. | 2002-07-18 | — | — | US | disclosed |
| US-6342610-B2 | COMPOUNDS SUCH AS N-(4-BROMO-3-METHYL-5-ISOXAZOLYL)-2-N-BENZYLBENZO(B)THIOPHENE-3-SUFONAMIDE ADMINISTERED AS ENDOTHELIN PEPTIDE RECEPTOR ANTAGONISTS | TEXAS BIOTECHNOLOGY CORP. | 2002-01-29 | — | — | US | disclosed |
| US-6331637-B1 | N-Alkyl, N-Alkenyl, N-Alkynyl, N-Aryl and N-fused bicyclo or tricyclo thienyl-, furyl-,and Pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin | TEXAS BIOTECHNOLOGY CORPORATION | 2001-12-18 | — | — | US | disclosed |
| US-20010021714-A1 | THIENYL-, FURYL-, PYRROLYL- AND BIPHENYLSULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | ENCYSIVE PHARMACEUTICALS INC. | 2001-09-13 | — | — | US | disclosed |
| EP-1048657-A1 | Thienyl-, furyl-, pyrrolyl- and biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2000-11-02 | — | — | EP | disclosed |
| US-5962490-A | Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1999-10-05 | — | — | US | disclosed |
| US-5594021-A | VASOCONSTRICTORS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1997-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010021714-A1 | THIENYL-, FURYL-, PYRROLYL- AND BIPHENYLSULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | EDNRA, EDNRB, NPSR1 | TUBB4A 4623/4885TUBB 4499/4885TUBA3C 4380/4885 |
| US-20020095041-A1 | Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin | EDNRB, EDNRA, ECE2 | TUBB4A 4796/4885TUBB 4717/4885TUBA3C 4800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.